Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H18O2 |
Molecular Weight | 278.345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12COC(=O)[C@]1(CC3=CC=C4C=CC=CC4=C3)CC(=C)C2
InChI
InChIKey=CVIRWLJKDBYYOG-MJGOQNOKSA-N
InChI=1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1
Molecular Formula | C19H18O2 |
Molecular Weight | 278.345 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
BAY-36-7620 is a potent and selective antagonist at mGlu1receptors and inhibits >60% of mGlu1a receptor constitutive activity (IC50 = 0.38 uM). BAY-36-7620 is thus the first described mGlu1 receptor inverse agonist. It impairs classical conditioning and associated synaptic plasticity in hippocampal neurons. BAY-36-7620 exhibits neuroprotective and anticonvulsive effects in vivo following systemic administration.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3772 |
0.16 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25613036 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. | 2001 May |
|
Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. | 2001 Oct 5 |
|
Glutamate metabotropic receptors as targets for drug therapy in epilepsy. | 2003 Aug 22 |
|
[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. | 2003 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21681448
Mice: BAY-36-7620 was given i.p. once a day, at a single dose level of 10 mg/kg. Treatment of mice bearing MDA-MB-231 xenografts with BAY-36-7620, by intraperitoneal injection, resulted in a significant reduction in tumor volume of up to 80%.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11306677
To test for an antagonistic effect of BAY-36-7620 on mGlu1 or mGlu5 receptors, HEK 293 cells were stimulated with a Glu concentration around its EC50 value (1 uM for mGlu1a & 5 uM for mGlu5a), in the presence of BAY-36-7620, applied at a concentration of 0.1 or 10 uM. A strong inhibition of the Glu effect (61 ± 3 % inhibition) was observed with 0.1 uM BAY-36-7620 and a total inhibition was observed with 10 uM BAY-36-7620 on mGlu1 receptors whereas no effect was seen on mGlu5 receptors. The antagonist effect of BAY-36-7620 on mGlu1a receptors was concentration-dependent with an IC50 of 0.16 ± 0.01 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:44:18 GMT 2023
by
admin
on
Sat Dec 16 09:44:18 GMT 2023
|
Record UNII |
0P934RSF8B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9903757
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY | |||
|
232605-26-4
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY | |||
|
0P934RSF8B
Created by
admin on Sat Dec 16 09:44:18 GMT 2023 , Edited by admin on Sat Dec 16 09:44:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |